STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL

被引:686
作者
Rodbard, Helena W.
Jellinger, Paul S.
Davidson, Jaime A.
Einhorn, Daniel
Garber, Alan J.
Grunberger, George
Handelsman, Yehuda
Horton, Edward S.
Lebovitz, Harold
Levy, Philip
Moghissi, Etie S.
Schwartz, Stanley S.
Gavin, James R., III
机构
关键词
GLUCOSE CONTROL; EUROPEAN-ASSOCIATION; CARDIOVASCULAR-DISEASE; HYPERGLYCEMIA; HYPOGLYCEMIA; ADJUSTMENT; MANAGEMENT; INITIATION; THERAPY; PHARMACOKINETICS;
D O I
10.4158/EP.15.6.540
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This report presents an algorithm to assist primary care physicians, endocrinologists, and others in the management of adult, nonpregnant patients with type 2 diabetes mellitus. In order to minimize the risk of diabetes-related complications, the goal of therapy is to achieve a hemoglobin Alc (AlC) of 6.5% or less, with recognition of the need for individualization to minimize the risks of hypoglycemia. We provide therapeutic pathways stratified on the basis of current levels of AlC, whether the patient is receiving treatment or is drug naive. We consider monotherapy, dual therapy, and triple therapy, including 8 major classes of medications (biguanides, dipeptidyl-peptidase-4 inhibitors, incretin mimetics, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, meglitinides, and bile acid sequestrants) and insulin therapy (basal, premixed, and multiple daily injections), with or without orally administered medications. We prioritize choices of medications according to safety, risk of hypoglycemia, efficacy, simplicity, anticipated degree of patient adherence, and cost of medications. We recommend only combinations of medications approved by the US Food and Drug Administration that provide complementary mechanisms of action. It is essential to monitor therapy with A1C and self-monitoring of blood glucose and to adjust or advance therapy frequently (every 2 to 3 months) if the appropriate goal for each patient has not been achieved. We provide a flowchart and table summarizing the major considerations. This algorithm represents a consensus of 14 highly experienced clinicians, clinical researchers, practitioners, and academicians and is based on the American Association of Clinical Endocrinologists/American College of Endocrinology Diabetes Guidelines and the recent medical literature. (Endocr Pract. 2009;15:540-559)
引用
收藏
页码:540 / 559
页数:20
相关论文
共 42 条
[1]   Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function Implications for Rigorous Glycemic Control [J].
Adler, Gail K. ;
Bonyhay, Istvan ;
Fainng, Hannah ;
Waring, Elizabeth ;
Dotson, Sarah ;
Freeman, Roy .
DIABETES, 2009, 58 (02) :360-366
[2]   Hypoglycaemia in Type 2 diabetes [J].
Amiel, S. A. ;
Dixon, T. ;
Mann, R. ;
Jameson, K. .
DIABETIC MEDICINE, 2008, 25 (03) :245-254
[3]   Executive Summary: Standards of Medical Care in Diabetes-2009 [J].
不详 .
DIABETES CARE, 2009, 32 :S6-S12
[4]  
[Anonymous], 2005, Global guideline for type 2 diabetes
[5]  
[Anonymous], ENDOCR PRACT, DOI [10.4158/EP.8.6.439, DOI 10.4158/EP.8.6.439]
[6]  
Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424
[7]  
BEASER RS, 2007, JOSLINS DIABETES DES, pCH8
[8]   An interaction between digoxin and acarbose [J].
Ben-Ami, H ;
Krivoy, N ;
Nagachandran, P ;
Roguin, A ;
Edoute, Y .
DIABETES CARE, 1999, 22 (05) :860-861
[9]   Cardiovascular Therapies and Associated Glucose Homeostasis Implications Across the Dysglycemia Continuum [J].
Cooper-DeHoff, Rhonda M. ;
Pacanowski, Michael A. ;
Pepine, Carl J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (05) :S28-S34
[10]  
Cryer Philip E, 2008, Endocr Pract, V14, P750